Fetuin-A, through its association with inflammatory processes, insulin resistance, and cardiovascular risk, may in the future be applied in identifying metabolically burdened patients as well as in monitoring treatment efficacy in individuals with chronic kidney disease. Here, AHSG is linked to chronic kidney disease.